Results 21 to 30 of about 50,237 (216)

Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer

Cell Death and Disease, 2021
Cetuximab is approved for the treatment of metastatic colorectal cancer (mCRC) with RAS wild-type. Nevertheless, the prognosis remains poor and the effectiveness of cetuximab is limited in KRAS mutant mCRC.
Jiawen Yang, Jiajie Mo, Juji Dai, Chenqiao Ye, Wei Cen, Xuzhi Zheng, Lei Jiang, Lechi Ye   +7 more
doaj   +1 more source

Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies

Pharmacology Research & Perspectives, 2019
The pharmacokinetics and potential drug–drug interactions between cetuximab and cisplatin or carboplatin from two studies (JXBA and JXBB) were evaluated.
Raymond P. Perez, Eric Chen, J. Thaddeus Beck, Keisuke Shirai, David Neil Hayes, Tong Shen, John R. Baldwin, Katherine B. Bryant, Shuang He, Steve Chin   +9 more
doaj   +1 more source

Platycodin D sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the PI3K/Akt signaling pathway

Frontiers in Oncology, 2022
Cetuximab is a monoclonal antibody against epidermal growth factor receptor that blocks downstream signaling pathways of receptor tyrosine kinases, including Ras/Raf/MAPK and PI3K/Akt, thereby inhibiting tumor cell proliferation and inducing cancer cell ...
Yanfei Liu, Yanfei Liu, Shifeng Tian, Ben Yi, Ben Yi, Zhiqiang Feng, Zhiqiang Feng, Tianhao Chu, Tianhao Chu, Jun Liu, Chunze Zhang, Shiwu Zhang, Yijia Wang   +12 more
doaj   +1 more source

Long noncoding RNA and mRNA profiling in cetuximab‐resistant colorectal cancer cells by RNA sequencing analysis

Cancer Medicine, 2019
To gain an insight into the molecular mechanisms of cetuximab resistance in colorectal cancer, we generated a cetuximab‐resistant cell line (H508/CR) and performed RNA sequencing to identify the differential expression patterns of noncoding RNAs (ncRNAs)
Changwen Jing, Rong Ma, Haixia Cao, Zhuo Wang, Siwen Liu, Dan Chen, Yang Wu, Junying Zhang, Jianzhong Wu   +8 more
doaj   +1 more source

Immuno-PET imaging for non-invasive assessment of cetuximab accumulation in non-small cell lung cancer

BMC Cancer, 2019
Backgrounds Overexpression of epidermal growth factor receptor (EGFR) has been established as a valid therapeutic target of non-small cell lung cancer (NSCLC).
Aiko Yamaguchi, Arifudin Achmad, Hirofumi Hanaoka, Yusri Dwi Heryanto, Anu Bhattarai, Ratianto, Erdene Khongorzul, Rini Shintawati, A. Adhipatria P. Kartamihardja, Ayaka Kanai, Yumi Sugo, Noriko S. Ishioka, Tetsuya Higuchi, Yoshito Tsushima   +13 more
doaj   +1 more source

ACACB is a novel metabolism-related biomarker in the prediction of response to cetuximab therapy inmetastatic colorectal cancer

Acta Biochimica et Biophysica Sinica, 2022
Cetuximab is one of the most valuable targeted therapy monoclonal antibodies in the treatment of metastatic colorectal cancer (CRC). However, the mechanisms affecting cetuximab resistance in CRC treatment remain unclear. Metabolism, especially fatty acid
Hong Hi-Ju, Shao Yanfei, Zhang Sen, Yang Guang, Jia Hongtao, Yang Xiao, Huang Ling, Li Shuchun, Aikemu Batuer, Zhang Luyang, Ma Junjun, Zang Lu, Sun Jing, Zheng Minhua   +13 more
doaj   +1 more source

In vivo efficacy of Abemaciclib and Cetuximab in CF555 chordoma xenograft model_CF40

, 2021
DrugTargetsAbemaciclib + CetuximabCDK4/6 + EGFRDose50mg/kg (Abemaciclib) 20mg/kg (Cetuximab)RoutePO (Abemaciclib) IP (Cetuximab)Scheduleqd to end (Abemaciclib) 2xwklyx6 (Cetuximab) Duration of treatment42 dStrain of miceAthymic NudeTGI (day)93% (Day 42)p-
Dan Freed (4391989)
core   +1 more source

Infectious complications in head and neck cancer patients treated with cetuximab: propensity score and instrumental variable analysis.

PLoS ONE, 2012
BackgroundTo compare the infection rates between cetuximab-treated patients with head and neck cancers (HNC) and untreated patients.MethodologyA national cohort of 1083 HNC patients identified in 2010 from the Taiwan National Health Insurance Research ...
Ching-Chih Lee, Hsu-Chueh Ho, Shih-Hsuan Hsiao, Tza-Ta Huang, Hon-Yi Lin, Szu-Chin Li, Pesus Chou, Yu-Chieh Su   +7 more
doaj   +1 more source

Pharmacogenomics of cetuximab in metastatic colorectal carcinoma

, 2014
Cetuximab is a chimeric monoclonal antibody that has revolutionized the treatment of metastatic colorectal cancer. Knowledge of the mechanisms that underlie its effectiveness, as well as the primary and secondary resistance mechanisms, have led to ...
Vincenzi, Bruno, Silvestris, Nicola, Silvestris N., Dell'Aquila E., Giampieri R., Russo Antonio, Giampieri Riccardo, Vincenzi B., Giampieri, Riccardo, Silvestris Nicola, Vincenzi Bruno, Santini, Daniele, Lorusso V., Scartozzi Mario, Tonini G., Loupakis Fotious, Falcone Alfredo, Loupakis F., Cascinu Stefano, Loupakis, Fotious, Brunetti, Anna Elisabetta, Tonini, Giuseppe, Cascinu, Stefano, Dell'Aquila Emanuela, Lorusso, Vito, Santini D., Falcone A., Vincenzi B, Lorusso Vito, Santini Daniele, Falcone, Alfredo, Brunetti A. E., Russo, Antonio, Brunetti Anna Elisabetta, Dell'Aquila, Emanuela, Scartozzi M., Tonini Giuseppe, SCARTOZZI, MARIO, Cascinu S., Russo A.   +39 more
core   +2 more sources

Ligand‐Directed Molecular Beacons as Turn‐On Fluorescent Probes for Sensing Cell‐Surface Receptor‐Ligand Interactions

Angewandte Chemie, EarlyView.
Multivalent, ligand‐directed molecular beacons enable fluorescence turn‐on detection of cell‐surface receptors in living cells. The probes strongly engage closely spaced membrane receptors and exhibit conformation‐dependent fluorescence enhancement at the cell surface, enabling wash‐free receptor imaging, inhibitor screening, and functional evaluation ...
Noa Oppenheimer‐Low, Denis Shpalter, Suraj Toraskar, Martín López‐Vidal, Ziv Porat, Inna Goliand, Ekaterina Petrovich‐Kopitman, Noga Kozer, Haim Michael Barr, Alla H. Falkovich, Leila Motiei, David Margulies   +11 more
wiley   +2 more sources